Mycenax Biotech Inc. (4726) announced that it has entered into a non-binding Term Sheet with its Japanese strategic partners—Alfresa Holdings Corporation (Alfresa), Kidswell Bio Corporation (Kidswell), and Chiome Bioscience Inc. (Chiome), and will actively engage in discussions about establishing a joint venture in Japan based on the Term Sheet, aiming to build a biopharmaceutical GMP manufacturing facility equipped with both Drug Substance (DS) and Drug Product (DP) capabilities while expanding biologics CDMO and distribution business.
This joint venture plan originates from the “Subsidy Program for the Development of Domestic Manufacturing Facilities for Biosimilars” promoted by MHLW of Japan, which aims to establish a stable domestic supply chain for biosimilars. The three Japanese partners were approved for this subsidy, and Mycenax is a key partner in this program.
The establishment of the joint venture will combine the strengths of all four parties: Alfresa’s extensive resource in pharmaceutical distribution, Kidswell’s experience in biosimilar development and commercialization, Chiome’s expertise in novel biologics R&D, and Mycenax’s process development and manufacturing capability in biologics, as well as the proven track record in CDMO services. Chairman Pei-Jiun Chen expressed that Mycenax has been operating in Japanese market for several years and collaborate smoothly with many biopharma and biotech companies. Through this alliance with three partners, Mycenax aligns with the Japanese government policy of manufacturing biologics domestically. Mycenax’s target is to further strengthen its market foundation in Japan and offer its customers integrated and comprehensive manufacturing site options.
Currently, Mycenax is already the commercial supplier of two internationally approved biologics. By entering into this non-binding term sheet with our strategic partners, Mycenax is advancing its plan to establish a biopharmaceutical manufacturing base in Japan, while continuously focusing on technological innovation and global market expansion, further enhancing its international competitiveness and realizing its vision of becoming a world-renowned Bio-CDMO.
Mycenax Biotech Inc. (4726) announced that it has entered into a non-binding Term Sheet with its Japanese strategic partners—Alfresa Holdings Corporation (Alfresa), Kidswell Bio Corporation (Kidswell), and Chiome Bioscience Inc. (Chiome), and will actively engage in discussions about establishing a joint venture in Japan based on the Term Sheet, aiming to build a biopharmaceutical GMP manufacturing facility equipped with both Drug Substance (DS) and Drug Product (DP) capabilities while expanding biologics CDMO and distribution business.
This joint venture plan originates from the “Subsidy Program for the Development of Domestic Manufacturing Facilities for Biosimilars” promoted by MHLW of Japan, which aims to establish a stable domestic supply chain for biosimilars. The three Japanese partners were approved for this subsidy, and Mycenax is a key partner in this program.
The establishment of the joint venture will combine the strengths of all four parties: Alfresa’s extensive resource in pharmaceutical distribution, Kidswell’s experience in biosimilar development and commercialization, Chiome’s expertise in novel biologics R&D, and Mycenax’s process development and manufacturing capability in biologics, as well as the proven track record in CDMO services. Chairman Pei-Jiun Chen expressed that Mycenax has been operating in Japanese market for several years and collaborate smoothly with many biopharma and biotech companies. Through this alliance with three partners, Mycenax aligns with the Japanese government policy of manufacturing biologics domestically. Mycenax’s target is to further strengthen its market foundation in Japan and offer its customers integrated and comprehensive manufacturing site options.
Currently, Mycenax is already the commercial supplier of two internationally approved biologics. By entering into this non-binding term sheet with our strategic partners, Mycenax is advancing its plan to establish a biopharmaceutical manufacturing base in Japan, while continuously focusing on technological innovation and global market expansion, further enhancing its international competitiveness and realizing its vision of becoming a world-renowned Bio-CDMO.
